This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, R. N.
Right arrow Articles by Pectol, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, R. N.
Right arrow Articles by Pectol, R. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2000, p. 164-166, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Ciprofloxacin, Lomefloxacin, or Levofloxacin as Treatment for Chronic Osteomyelitis

Richard N. Greenberg,1,* Michael T. Newman,1 Saeed Shariaty,1 and Richard W. Pectol2

Departments of Medicine1 and Orthopedic Surgery,2 University of Kentucky Medical Center, Lexington, Kentucky 40536-0084

Received 1 February 1999/Returned for modification 24 July 1999/Accepted 11 October 1999

The efficacy and safety of three oral fluoroquinolones (lomefloxacin, levofloxacin, and ciprofloxacin) for the treatment of chronic osteomyelitis were analyzed. Twenty-seven patients had documented infections with quinolone-sensitive organisms and received either lomefloxacin, levofloxacin, or ciprofloxacin. Levofloxacin was effective therapy for 9 of 15 (60%) patients. Lomefloxacin was effective therapy for five of seven (71%) patients, and ciprofloxacin was effective therapy for two of five patients (40%). Average follow-up was 11.8 months for patients who completed the course of therapy, and the average duration of therapy was 60.6 days. Gram-positive bacteria were isolated from 18 patients, and 11 patients were cured. Oral fluoroquinolones can be safe, effective therapy if they are given for a prolonged course as treatment for infections caused by susceptible gram-positive as well as gram-negative organisms and in combination with adequate surgical debridement.

* Corresponding author. Mailing address: MN-668A, Division of Infectious Diseases, 800 Rose St., Lexington, KY 40536-0084. Phone: (606) 323-6327. Fax: (606) 323-1020. E-mail: RNGREE01{at}POP.UKY.EDU.

Antimicrobial Agents and Chemotherapy, January 2000, p. 164-166, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Frippiat, F., Meunier, F., Derue, G. (2004). Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 54: 1158-1158 [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P. (2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 1503-1509 [Abstract] [Full Text]  
  • Williams, J. H. Jr (2001). Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse. Chest 120: 1771-1775 [Full Text]  
  • Shirtliff, M. E., Calhoun, J. H., Mader, J. T. (2001). Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 48: 253-258 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»